Biogen
BIIB
966 hedge funds and large institutions have $90B invested in Biogen in 2015 Q1 according to their latest regulatory filings, with 133 funds opening new positions, 336 increasing their positions, 371 reducing their positions, and 42 closing their positions.
217% more first-time investments, than exits
New positions opened: 133 | Existing positions closed: 42
31% more funds holding in top 10
Funds holding in top 10: 52 → 68 (+16)
25% more capital invested
Capital invested by funds: $72.3B → $90B (+$17.7B)
9% more funds holding
Funds holding: 884 → 966 (+82)
9% less repeat investments, than reductions
Existing positions increased: 336 | Existing positions reduced: 371
35% less call options, than puts
Call options by funds: $1.06B | Put options by funds: $1.64B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$888M |
| 2 |
JSP
Jackson Square Partners
Larkspur,
California
|
+$409M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$367M |
| 4 |
D.E. Shaw & Co
New York
|
+$281M |
| 5 |
IC
Institutional Capital
Chicago,
Illinois
|
+$260M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$546M |
| 2 |
JP Morgan Chase
New York
|
-$442M |
| 3 |
Primecap Management
Pasadena,
California
|
-$241M |
| 4 |
Goldman Sachs
New York
|
-$212M |
| 5 |
Jennison Associates
New York
|
-$207M |
BIIB Hedge Fund Activity: Q1 2015 in Review
966 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2015, worth a combined $90B — up 25% from $72.3B a quarter earlier.
Buyers outnumbered sellers: 133 funds opened new BIIB positions and 42 closed out — a net gain of 91 holders — while 336 added to existing stakes and 371 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $888M. The largest seller was T. Rowe Price Associates, cutting an estimated $546M.
- 966 institutional investors held Biogen (BIIB) as of Q1 2015, up from 884 in Q4 2014.
- Funds reported $90B of Biogen stock for Q1 2015, up 25% quarter-over-quarter.
- 133 funds opened new Biogen positions in Q1 2015 and 42 closed out, a net change of +91 holders.
- The largest Biogen buyer in Q1 2015 was Fidelity Investments, an estimated $888M added.
- The largest Biogen seller in Q1 2015 was T. Rowe Price Associates, an estimated $546M sold.
Based on aggregated 13F filings for Q1 2015.